{"id":34228,"date":"2025-05-27T14:54:56","date_gmt":"2025-05-27T06:54:56","guid":{"rendered":"https:\/\/flcube.com\/?p=34228"},"modified":"2025-05-27T14:54:57","modified_gmt":"2025-05-27T06:54:57","slug":"gilead-sciences-to-acquire-hookipas-hb-400-and-hb-500-vaccine-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34228","title":{"rendered":"Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs"},"content":{"rendered":"\n

US-based Gilead Sciences Inc. (Nasdaq: GILD<\/a>) announced plans to acquire the HB-400 and HB-500 programs from its compatriot partner Hookipa Pharma Inc. for a total of USD 10 million. This strategic move expands Gilead’s portfolio in the development of therapeutic vaccines for chronic infectious diseases.<\/p>\n\n\n\n

HB-400 Program<\/strong>
HB-400 is an arenavirus-based therapeutic vaccine targeting chronic hepatitis B virus (HBV). It comprises two viral vector components, GS-2829 and GS-6779, developed using Hookipa Pharma’s non-replicating arenavirus vector platform. These vectors, derived from lymphocytic choriomeningitis virus (LCMV) and vesicular stomatitis virus (VSV), are engineered to express HBV antigens. Phase I clinical trial data showed that both single and alternating vector administration were safe and well-tolerated, with dose-dependent immune responses and enhanced T-cell responses observed in some participants.<\/p>\n\n\n\n

HB-500 Program<\/strong>
HB-500 is an arenavirus-based therapeutic vaccine targeting HIV. It employs two replication-competent vectors based on Pichinde virus (PICV) and lymphocytic choriomeningitis virus (LCMV). These vectors deliver HIV antigens from highly conserved regions of HIV-1 proteins. In January 2025, Hookipa announced the completion of enrollment for its Phase Ib clinical trial evaluating HB-500 in HIV, involving 30 participants. The trial is expected to reach its primary endpoint in the second half of 2025. Under a recently signed agreement, Hookipa will gradually wind down the Phase I study of HB-500.<\/p>\n\n\n\n

Collaboration Background<\/strong>
Gilead’s partnership with Hookipa dates back to 2018, when Gilead first licensed Hookipa’s arenavirus immunotherapy platform for HBV and HIV. Although Gilead decided not to advance the resulting HIV candidate to clinical development in 2021, the collaboration was renegotiated in 2022. At that time, Gilead provided a USD 15 million upfront payment and a USD 5 million equity investment. The original agreement included potential payments of USD 10 million for program completion, up to USD 162.5 million in development milestones, and up to USD 65 million in commercial milestones.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs…<\/p>\n","protected":false},"author":1,"featured_media":34230,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[226,631,4099,1025,12,89],"class_list":["post-34228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-gilead-sciences","tag-hiv-aids-care","tag-hookipa-pharma","tag-nasdaq-gild","tag-vaccine","tag-viral-hepatitis"],"yoast_head":"\nGilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs from its compatriot partner Hookipa Pharma Inc. for a total of USD 10 million. This strategic move expands Gilead's portfolio in the development of therapeutic vaccines for chronic infectious diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34228\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs\" \/>\n<meta property=\"og:description\" content=\"US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs from its compatriot partner Hookipa Pharma Inc. for a total of USD 10 million. This strategic move expands Gilead's portfolio in the development of therapeutic vaccines for chronic infectious diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34228\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T06:54:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T06:54:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2710.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs\",\"datePublished\":\"2025-05-27T06:54:56+00:00\",\"dateModified\":\"2025-05-27T06:54:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228\"},\"wordCount\":312,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2710.webp\",\"keywords\":[\"Gilead Sciences\",\"HIV \\\/ AIDS care\",\"Hookipa Pharma\",\"NASDAQ: GILD\",\"Vaccine\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34228#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34228\",\"name\":\"Gilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2710.webp\",\"datePublished\":\"2025-05-27T06:54:56+00:00\",\"dateModified\":\"2025-05-27T06:54:57+00:00\",\"description\":\"US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs from its compatriot partner Hookipa Pharma Inc. for a total of USD 10 million. This strategic move expands Gilead's portfolio in the development of therapeutic vaccines for chronic infectious diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34228\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2710.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2710.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34228#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs - Insight, China's Pharmaceutical Industry","description":"US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs from its compatriot partner Hookipa Pharma Inc. for a total of USD 10 million. This strategic move expands Gilead's portfolio in the development of therapeutic vaccines for chronic infectious diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34228","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs","og_description":"US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs from its compatriot partner Hookipa Pharma Inc. for a total of USD 10 million. This strategic move expands Gilead's portfolio in the development of therapeutic vaccines for chronic infectious diseases.","og_url":"https:\/\/flcube.com\/?p=34228","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-27T06:54:56+00:00","article_modified_time":"2025-05-27T06:54:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2710.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34228#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34228"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs","datePublished":"2025-05-27T06:54:56+00:00","dateModified":"2025-05-27T06:54:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34228"},"wordCount":312,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34228#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2710.webp","keywords":["Gilead Sciences","HIV \/ AIDS care","Hookipa Pharma","NASDAQ: GILD","Vaccine","Viral hepatitis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34228#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34228","url":"https:\/\/flcube.com\/?p=34228","name":"Gilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34228#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34228#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2710.webp","datePublished":"2025-05-27T06:54:56+00:00","dateModified":"2025-05-27T06:54:57+00:00","description":"US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs from its compatriot partner Hookipa Pharma Inc. for a total of USD 10 million. This strategic move expands Gilead's portfolio in the development of therapeutic vaccines for chronic infectious diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34228#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34228"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34228#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2710.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2710.webp","width":1080,"height":608,"caption":"Gilead Sciences to Acquire Hookipa's HB-400 and HB-500 Vaccine Programs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34228#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2710.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34228"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34228\/revisions"}],"predecessor-version":[{"id":34231,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34228\/revisions\/34231"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34230"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}